- 同
- B-cell-activating factor of TNF family receptor
WordNet
- the 18th letter of the Roman alphabet (同)r
- a tributary of the Mississippi River that flows eastward from Texas along the southern boundary of Oklahoma and through Louisiana (同)Red River
PrepTutorEJDIC
- resistance / 17歳以下父兄同伴映画の表示 / rook
- roentgen / recto
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2017/11/07 01:45:05」(JST)
[Wiki en表示]
TNFRSF13C |
|
Available structures |
PDB |
Ortholog search: PDBe RCSB |
List of PDB id codes |
1MPV, 1OQE, 1OSX, 2HFG, 3V56, 4V46
|
|
|
Identifiers |
Aliases |
TNFRSF13C, BAFF-R, BAFFR, BROMIX, CD268, CVID4, prolixin, tumor necrosis factor receptor superfamily member 13C, TNF receptor superfamily member 13C |
External IDs |
MGI: 1919299 HomoloGene: 49897 GeneCards: TNFRSF13C |
Gene location (Human) |
|
Chr. |
Chromosome 22 (human)[1] |
|
Band |
22q13.2 |
Start |
41,922,023 bp[1] |
End |
41,926,818 bp[1] |
|
Gene location (Mouse) |
|
Chr. |
Chromosome 15 (mouse)[2] |
|
Band |
15|15 E1 |
Start |
82,221,744 bp[2] |
End |
82,224,339 bp[2] |
|
Orthologs |
Species |
Human |
Mouse |
Entrez |
|
|
Ensembl |
|
|
UniProt |
|
|
RefSeq (mRNA) |
|
|
RefSeq (protein) |
|
|
Location (UCSC) |
Chr 22: 41.92 – 41.93 Mb |
Chr 22: 82.22 – 82.22 Mb |
PubMed search |
[3] |
[4] |
Wikidata |
View/Edit Human |
View/Edit Mouse |
|
BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF.[5] In humans it is encoded by the TNFRSF13C gene.[6]
Contents
- 1 Function
- 2 Clinical significance
- 3 See also
- 4 References
- 5 External links
- 6 Further reading
Function
B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. The protein encoded by this gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular phenylalanine-rich domain. It is thought that this receptor is the principal receptor required for BAFF-mediated mature B-cell survival.[6]
Clinical significance
Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.[6]
See also
- B-cell maturation antigen
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000159958 - Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000068105 - Ensembl, May 2017
- ^ "Human PubMed Reference:".
- ^ "Mouse PubMed Reference:".
- ^ Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, Strauch K, Zafari M, Benjamin CD, Tschopp J, Browning JL, Ambrose C (Sep 2001). "BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF". Science. 293 (5537): 2108–11. doi:10.1126/science.1061965. PMID 11509692.
- ^ a b c "Entrez Gene: TNFRSF13C tumor necrosis factor receptor superfamily, member 13C".
External links
- Human TNFRSF13C genome location and TNFRSF13C gene details page in the UCSC Genome Browser.
Further reading
- Laâbi Y, Egle A, Strasser A (Dec 2001). "TNF cytokine family: more BAFF-ling complexities". Current Biology. 11 (24): R1013–6. doi:10.1016/S0960-9822(01)00613-3. PMID 11747837.
- Defrance T, Casamayor-Pallejà M, Krammer PH (2003). "The life and death of a B cell". Advances in Cancer Research. 86: 195–225. doi:10.1016/S0065-230X(02)86006-7. PMID 12374279.
- Ambrose CM (2003). "BAFF-R". Journal of Biological Regulators and Homeostatic Agents. 16 (3): 211–3. PMID 12456020.
- Bossen C, Schneider P (Oct 2006). "BAFF, APRIL and their receptors: structure, function and signaling". Seminars in Immunology. 18 (5): 263–75. doi:10.1016/j.smim.2006.04.006. PMID 16914324.
- Treml LS, Crowley JE, Cancro MP (Oct 2006). "BLyS receptor signatures resolve homeostatically independent compartments among naïve and antigen-experienced B cells". Seminars in Immunology. 18 (5): 297–304. doi:10.1016/j.smim.2006.07.001. PMID 16919470.
- Kalled SL (Oct 2006). "Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production". Seminars in Immunology. 18 (5): 290–6. doi:10.1016/j.smim.2006.06.002. PMID 16931038.
- Mackay F, Leung H (Oct 2006). "The role of the BAFF/APRIL system on T cell function". Seminars in Immunology. 18 (5): 284–9. doi:10.1016/j.smim.2006.04.005. PMID 16931039.
- Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (Jun 1999). "BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth". The Journal of Experimental Medicine. 189 (11): 1747–56. doi:10.1084/jem.189.11.1747. PMC 2193079 . PMID 10359578.
- Hartley JL, Temple GF, Brasch MA (Nov 2000). "DNA cloning using in vitro site-specific recombination". Genome Research. 10 (11): 1788–95. doi:10.1101/gr.143000. PMC 310948 . PMID 11076863.
- Yan M, Brady JR, Chan B, Lee WP, Hsu B, Harless S, Cancro M, Grewal IS, Dixit VM (Oct 2001). "Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency". Current Biology. 11 (19): 1547–52. doi:10.1016/S0960-9822(01)00481-X. PMID 11591325.
- Rolink AG, Melchers F (Apr 2002). "BAFFled B cells survive and thrive: roles of BAFF in B-cell development". Current Opinion in Immunology. 14 (2): 266–75. doi:10.1016/S0952-7915(02)00332-1. PMID 11869903.
- Xu LG, Shu HB (Dec 2002). "TNFR-associated factor-3 is associated with BAFF-R and negatively regulates BAFF-R-mediated NF-kappa B activation and IL-10 production". Journal of Immunology. 169 (12): 6883–9. doi:10.4049/jimmunol.169.12.6883. PMID 12471121.
- Kim HM, Yu KS, Lee ME, Shin DR, Kim YS, Paik SG, Yoo OJ, Lee H, Lee JO (May 2003). "Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation". Nature Structural Biology. 10 (5): 342–8. doi:10.1038/nsb925. PMID 12715002.
- Liu Y, Hong X, Kappler J, Jiang L, Zhang R, Xu L, Pan CH, Martin WE, Murphy RC, Shu HB, Dai S, Zhang G (May 2003). "Ligand-receptor binding revealed by the TNF family member TALL-1". Nature. 423 (6935): 49–56. doi:10.1038/nature01543. PMID 12721620.
- Gordon NC, Pan B, Hymowitz SG, Yin J, Kelley RF, Cochran AG, Yan M, Dixit VM, Fairbrother WJ, Starovasnik MA (May 2003). "BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site". Biochemistry. 42 (20): 5977–83. doi:10.1021/bi034017g. PMID 12755599.
PDB gallery
|
|
1oqe: Crystal structure of sTALL-1 with BAFF-R
|
|
1osx: Solution Structure of the Extracellular Domain of BLyS Receptor 3 (BR3)
|
|
1p0t: Crystal Structure of the BAFF-BAFF-R complex (part II)
|
|
2hfg: Crystal structure of hBR3 bound to CB3s-Fab
|
|
|
Cytokine receptors
|
Chemokine receptor
(GPCRs) |
CC |
- CCR1 / CCRL1
- CCR2
- CCRL2
- CCR3
- CCR4
- CCR5
- CCR6
- CCR7
- CCR8
- CCR9
- CCR10
|
CXC |
- IL-8
- CXCR3
- CXCR4
- CXCR5
- CXCR6
- CXCR7
|
Other |
|
|
TNF receptor |
1-10 |
- TNFR1 (TNFRSF1A)
- TNFR2 (TNFRSF1B)
- LTBR (TNFRSF3)
- CD134 (TNFRSF4)
- CD40 (TNFRSF5)
- Fas receptor (TNFRSF6)
- DcR3 (TNFRSF6B)
- CD27 (TNFRSF7)
- CD30 (TNFRSF8)
- CD137 (TNFRSF9)
|
11-20 |
- DR4 (TNFRSF10A)
- DR5 (TNFRSF10B)
- DcR1 (TNFRSF10C)
- DcR2 (TNFRSF10D)
- RANK (TNFRSF11A)
- Osteoprotegerin (TNFRSF11B)
- TweakR (TNFRSF12A)
- TACI (TNFRSF13B)
- BAFFR (TNFRSF13C)
- HVEM (TNFRSF14)
- NGFR (TNFRSF16)
- BCMA (TNFRSF17)
- GITR (TNFRSF18)
- TAJ/TROY (TNFRSF19)
|
21-27 |
- DR6 (TNFRSF21)
- DR3 (TNFRSF25)
- EDA2R (TNFRSF27)
|
|
JAK-STAT |
Type I |
γ-chain |
- Interleukin receptors
- IL2R / IL2RA/IL2RB / IL15R
- IL4R / IL13R / IL13RA1 / IL13RA2
- IL7R / IL7RA
- IL9R
- IL21R
|
β-chain |
- Interleukin receptors
- IL3R / IL3RA
- IL5R / IL5RA
- GM-CSF
|
gp130 |
- Interleukin receptors
- IL6RA
- 11/IL11RA
- 27/IL27RA
- OSMR
- LIFR
- CNTFR
|
IL12RB1 |
- Interleukin receptors
- IL12R/IL12RB1/IL12RB2
- IL23R23
|
Other |
- hormone receptor: GH
- prolactin
|
|
Type II |
- Interleukin receptors
- IL10R / IL10RA / IL10RB / IL22R / IL22RA1 / IL22RA2
- IL20R / IL20RA / IL20RB
- IL28R
- Interferon receptors
- -α/β / IFNAR1/IFNAR2
- -γ/IFNGR1 / IFNGR2
|
|
Ig superfamily |
- CSF1
- KIT
- IL1
- IL18R / IL18R1
|
IL 17 family |
- IL17
- IL17RA
- IL17RB
- IL17RC
- IL17RD
- IL17RE
|
S/T |
|
Cytokine receptor modulators
|
Chemokine |
|
CSF |
Erythropoietin |
- Agonists: ARA-290
- Asialo erythropoietin
- Carbamylated erythropoietin
- CNTO-530
- Darbepoetin alfa
- Epoetin alfa
- Epoetin beta
- Epoetin delta
- Epoetin epsilon
- Epoetin gamma
- Epoetin kappa
- Epoetin omega
- Epoetin theta
- Epoetin zeta
- Erythropoietin (EPO)
- Erythropoietin-Fc
- Methoxy polyethylene glycol-epoetin beta (CERA/Mircera)
- Peginesatide
- Pegol sihematide (EPO-018B)
|
G-CSF (CSF3) |
- Agonists: Filgrastim
- Granulocyte colony-stimulating factor
- Lenograstim
- Leridistim
- Lipegfilgrastim
- Nartograstim
- Pegfilgrastim
- Pegnartograstim
|
GM-CSF (CSF2) |
- Agonists: Ecogramostim
- Granulocyte macrophage colony-stimulating factor
- Milodistim
- Molgramostim
- Regramostim
- Sargramostim
- Antibodies: Mavrilimumab
- MOR103
- Namilumab
|
M-CSF (CSF1) |
- Agonists: Cilmostim
- Interleukin-34
- Lanimostim
- Macrophage colony-stimulating factor
- Mirimostim
- Kinase inhibitors: Agerafenib
|
SCF (c-Kit) |
|
Thrombopoietin |
- Agonists: Eltrombopag
- Pegacaristim
- Promegapoietin
- Romiplostim
- Thrombopoietin (THPO, MGDF)
|
|
Interferon |
IFNAR (α/β, I) |
- Agonists: Albinterferon
- Interferon alpha (interferon alfa, IFN-α)
- Interferon alfa (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21)
- Interferon alfa 2a
- Interferon alfa 2b
- Interferon alfa n1
- Interferon alfacon-1
- Interferon alpha-n3
- Interferon beta (IFN-β) (IFNB1, IFNB3)
- Interferon beta 1a
- Interferon beta 1b
- Interferon kappa (IFN-ε/κ/τ/ζ, IFNK)
- Interferon omega (IFN-ω, IFNW1)
- Peginterferon alfa-2a
- Peginterferon alfa-2b
- Antibodies: Anifrolumab
- Faralimomab
- MEDI-545
- Rontalizumab
- Sifalimumab
- Decoy receptors: Bifarcept
|
IFNGR (γ, II) |
- Agonists: Interferon gamma (IFN-γ)
- Interferon gamma 1b
- Antibodies: Emapalumab
- Fontolizumab
|
IFNLR (λ, III) |
- See IL-28R (IFNLR) here instead.
|
|
Interleukin |
|
TGFβ |
|
TNF |
|
Others |
JAK
(inhibitors) |
JAK1 |
- Baricitinib
- Filgotinib
- Momelotinib
- Oclacitinib
- Ruxolitinib
- Tofacitinib (tasocitinib, CP-690550)
- Upadacitinib
|
JAK2 |
- AG-490
- Atiprimod
- AZD-1480
- Baricitinib
- CHZ868
- Cucurbitacin I (elatericin B, JSI-124)
- CYT387
- Lestaurtinib
- NSC-7908
- NSC-33994
- Pacritinib
- Ruxolitinib
- SD-1008
- Tofacitinib (tasocitinib, CP-690550)
|
JAK3 |
- AG-490
- Cercosporamide
- TCS-21311
- Tofacitinib (tasocitinib, CP-690550)
- WHI-P 154
- ZM-39923
- ZM-449829
|
|
Others |
- Additional cytokines: Cardiotrophin 1 (CT-1)
- FMS-like tyrosine kinase 3 ligand (FLT3L)
- Leukemia/leukocyte inhibitory factor (LIF)
- Oncostatin M (OSM)
- Thymic stromal lymphopoietin (TSLP)
- Additional cytokine receptor modulators: Emfilermin
- Lestaurtinib
- Midostaurin
- Quizartinib
- Sorafenib
- Sunitinib
|
|
- See also
- Receptor/signaling modulators
- Signaling peptide/protein receptor modulators
- Growth factor receptor modulators
|
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- IFN type I and II induce BAFF secretion from human decidual stromal cells.
- Lundell AC1, Nordström I1, Andersson K1, Lundqvist C1, Telemo E1, Nava S2, Kaipe H2,3, Rudin A1.
- Scientific reports.Sci Rep.2017 Jan 6;7:39904. doi: 10.1038/srep39904.
- B cell activating factor (BAFF) is a critical cytokine for maturation of immature B cells. In murine lymph nodes, BAFF is mainly produced by podoplanin-expressing stromal cells. We have previously shown that circulating BAFF levels are maximal at birth, and that farmers' children exhibit higher BAFF
- PMID 28057926
- FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
- Li Y1,2, Bouchlaka MN2,3, Wolff J1, Grindle KM1,2, Lu L4, Qian S4, Zhong X4, Pflum N1, Jobin P1, Kahl BS1,2, Eickhoff JC5, Wuerzberger-Davis SM2,6, Miyamoto S2,6, Thomas CJ7, Yang DT2,8, Capitini CM2,3, Rui L1,2.
- Oncogene.Oncogene.2016 Dec 1;35(48):6223-6234. doi: 10.1038/onc.2016.155. Epub 2016 May 9.
- Targeting Bruton tyrosine kinase (BTK) by ibrutinib is an effective treatment for patients with relapsed/refractory mantle cell lymphoma (MCL). However, both primary and acquired resistance to ibrutinib have developed in a significant number of these patients. A combinatory strategy targeting multip
- PMID 27157620
- [Mechanism of Regulating BAFF Signaling Pathway by Act1 in B Cell Lymphoma].
- Wang YL1, Min X1, Ge XJ2.
- Zhongguo shi yan xue ye xue za zhi.Zhongguo Shi Yan Xue Ye Xue Za Zhi.2016 Dec;24(6):1787-1792.doi:10.7534/j.issn.1009-2137.2016.06.031.
- OBJECTIVE: To explore the mechanism of regulating B cell-activating factor (BAFF) signalling pathway by NF-κB activator 1 (Act1) in B cell lymphoma so as to provide a new thinking for treatment of B cell lymphoma.METHODS: The human B cell lymphoma cell lines including Raji, Daudi and BALL-1 were cu
- PMID 28024495
Japanese Journal
- P1-002 IgG4関連疾患における形質芽細胞の役割
- Immunohistochemical study of differential expressions of BR3 (BAFF-R) in malignant lymphomas of oral and maxillofacial regions
- P2-08 ヒト末梢単球におけるBAFF受容体(BAFF-R : BR3)発現機構の検討
Related Pictures
★リンクテーブル★
[★]
[★]